Q BioMed Company Description
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.
The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.
It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer.
Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others.
The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015.
Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
Contact Details
Address: 366 Madison Avenue New York, Nevada 10017 United States | |
| Phone | 212 588 0022 |
| Website | qbiomed.com |
Stock Details
| Ticker Symbol | QBIO |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | December - November |
| Reporting Currency | USD |
| ISIN Number | US74736N1054 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Denis D. Corin | Chairman, Chief Executive Officer and President |
| William S. Rosenstadt | Chief Legal Officer, General Counsel and Director |
| Ari Jatwes | Director of Finance |